Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMF3MV1)

• Drug Name: GDC-0980/RG7422 Drug Info
• Synonyms: Apitolisib; 1032754-93-0; GDC-0980; GDC0980; RG7422; (S)-1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one; UNII-1C854K1MIJ; GDC-0980 (RG7422); Apitolisib (GDC-0980, RG7422); 1C854K1MIJ; CHEMBL1922094; RG-7422; (2s)-1-(4-{[2-(2-Aminopyrimidin-5-Yl)-7-Methyl-4-(Morpholin-4-Yl)thieno[3,2-D]pyrimidin-6-Yl]methyl}piperazin-1-Yl)-2-Hydroxypropan-1-One; J-502360; C23H30N8O3S

Indication

Disease Entry	ICD 11	Status	REF
Non-hodgkin lymphoma	2B33.5	Phase 2	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]

• Cross-matching ID:
  PubChem CID: 25254071
  CAS Number: CAS 1032754-93-0
  TTD Drug ID: DMF3MV1

Molecule-Related Drug Atlas

Drug(s) Targeting Serine/threonine-protein kinase mTOR (mTOR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sirolimus	DMGW1ID	Advanced cancer	2A00-2F9Z	Approved	[7]
Temsirolimus	DMS104F	Renal cell carcinoma	2C90	Approved	[8]
PF-04449913	DMSB068	Chronic myelomonocytic leukaemia	2A40	Approved	[9]
Everolimus	DM8X2EH	Advanced cancer	2A00-2F9Z	Approved	[10]
Novolimus	DM6ZPLQ	Artery stenosis	BD52	Approved	[4]
Zotarolimus	DMRMCXW	Solid tumour/cancer	2A00-2F9Z	Approved	[11]
Ridaforolimus	DMLHEU7	Sarcoma	2A60-2C35	Phase 3	[12]
AZD2014	DMOEARH	Solid tumour/cancer	2A00-2F9Z	Phase 2	[13]
MM-141	DM2RJ4D	Pancreatic cancer	2C10	Phase 2	[14]
PQR309	DMMCYZ8	Squamous head and neck cell carcinom	2D60.0	Phase 2	[4]

Drug(s) Targeting PI3-kinase gamma (PIK3CG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BAY 80-6946	DMLOS5R	Follicular lymphoma	2A80	Approved	[15]
IPI-145	DMWA24P	Follicular lymphoma	2A80	Approved	[16]
Buparlisib	DM1WEHC	Breast cancer	2C60-2C65	Phase 3	[17]
Enzastaurin	DM5H0R9	Diffuse large B-cell lymphoma	2A81	Phase 3	[14]
Rigosertib	DMOSTXF	Myelodysplastic syndrome	2A37	Phase 3	[18]
GDC-0032	DMT4QHD	Breast cancer	2C60-2C65	Phase 3	[14]
PQR309	DMMCYZ8	Squamous head and neck cell carcinom	2D60.0	Phase 2	[19]
SAR245409	DMQM7IL	Solid tumour/cancer	2A00-2F9Z	Phase 2	[20]
XL147	DMML7BE	Solid tumour/cancer	2A00-2F9Z	Phase 2	[20]
SF1126	DML10K3	Head and neck cancer	2D42	Phase 2	[21]

Drug(s) Affected By Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform (PIK3CD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[22]
Selenium	DM25CGV	N. A.	N. A.	Approved	[23]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[24]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[25]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[26]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[27]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[28]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[29]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[30]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[31]

Drug(s) Affected By Poly polymerase 1 (PARP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[32]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[33]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[34]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[35]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[36]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[37]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[36]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[38]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[39]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[40]

Drug(s) Affected By G1/S-specific cyclin-D1 (CCND1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Indomethacin	DMSC4A7	Bursitis		Approved	[41]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[42]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[43]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[44]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[45]
Talazoparib	DM1KS78	Breast cancer	2C60-2C65	Approved	[46]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[47]
Selenium	DM25CGV	N. A.	N. A.	Approved	[23]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[48]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[49]

Drug(s) Affected By Mitogen-activated protein kinase 3 (MAPK3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[50]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[51]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[52]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[53]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[54]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[55]
Secobarbital	DM14RF5	Epilepsy	8A60-8A68	Approved	[56]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[57]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[58]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[59]

Drug(s) Affected By Mitogen-activated protein kinase 1 (MAPK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[60]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[51]
Carvedilol	DMHTEAO	Chronic heart failure	BD1Z	Approved	[61]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[62]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[63]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[50]
Urokinase	DM0GOUD	Myocardial infarction	BA41-BA43	Approved	[64]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[65]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[53]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[54]

Drug(s) Affected By Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform (PIK3CB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[66]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[67]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[25]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[68]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[69]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[70]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[27]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[71]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[64]
Tamibarotene	DM3G74J	T-cell leukaemia	2A90	Phase 3	[25]

Drug(s) Affected By Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform (PIK3CG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[72]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[25]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[68]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[26]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[73]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[74]
Tamibarotene	DM3G74J	T-cell leukaemia	2A90	Phase 3	[75]
Resveratrol	DM3RWXL	Giant cell arteritis	4A44.2	Phase 3	[76]
GDC0941	DM1YAK6	Breast cancer	2C60-2C65	Phase 2	[77]
Afimoxifene	DMFORDT	Breast cancer	2C60-2C65	Phase 2	[78]

Drug(s) Affected By Hepatocyte growth factor receptor (MET)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cabozantinib	DMIYDT4	Medullary thyroid gland carcinoma		Approved	[79]
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[80]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[81]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[81]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[81]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[82]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[83]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[81]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[84]
Methylprednisolone	DM4BDON	Acute adrenal insufficiency		Approved	[82]

Drug(s) Affected By Receptor tyrosine-protein kinase erbB-3 (ERBB3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[85]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[86]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[83]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[87]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[88]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[89]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[90]
Mitoxantrone	DMM39BF	Acute myelogenous leukaemia	2A41	Approved	[91]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[92]
Chloroquine	DMSI5CB	Malaria	1F40-1F45	Approved	[93]

Drug(s) Affected By Tuberin (TSC2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[94]
Selenium	DM25CGV	N. A.	N. A.	Approved	[23]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[95]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[96]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[26]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[97]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[98]
Methamphetamine	DMPM4SK	Anxiety		Approved	[99]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[100]
Azacitidine	DMTA5OE	Acute myelogenous leukaemia	2A41	Approved	[101]

Drug(s) Affected By Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[53]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[102]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[103]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[104]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[105]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[106]
Penicillamine	DM40EF6	Cystinuria	5C60.2	Approved	[107]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[102]
Glucosamine	DM4ZLFD	Osteoarthritis	FA00-FA05	Approved	[108]
Ethacrynic acid	DM60QMR	Edema	MG29	Approved	[109]

Drug(s) Affected By Eukaryotic translation initiation factor 4E-binding protein 1 (EIF4EBP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[110]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[48]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[111]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[112]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[113]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[114]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[115]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[116]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[89]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[117]

Drug(s) Affected By Cyclin-G2 (CCNG2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[118]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[83]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[119]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[87]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[118]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[120]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[121]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[122]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[122]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[69]

Drug(s) Affected By Atos homolog protein A (ATOSA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[122]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[122]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[83]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[122]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[122]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[122]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[27]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[122]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[123]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[124]

Drug(s) Affected By Phosphoinositide-3-kinase-interacting protein 1 (PIK3IP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[125]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[126]
Idelalisib	DM602WT	Chronic lymphocytic leukaemia	2A82.0	Approved	[127]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[114]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[128]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[129]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[129]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[89]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[26]
Motexafin gadolinium	DMEJKRF	Brain cancer	2A00	Approved	[126]

Drug(s) Affected By Serine/threonine-protein kinase STK11 (STK11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[130]
Selenium	DM25CGV	N. A.	N. A.	Approved	[23]
Ergotidine	DM78IME	Osteoarthritis	FA00-FA05	Approved	[131]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[26]
2-deoxyglucose	DMIAHVU	Solid tumour/cancer	2A00-2F9Z	Approved	[132]
Pioglitazone	DMKJ485	Amyotrophic lateral sclerosis	8B60.0	Approved	[133]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[134]
Resveratrol	DM3RWXL	Giant cell arteritis	4A44.2	Phase 3	[135]
APR-246	DMNFADH	Ovarian cancer	2C73	Phase 2	[136]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[137]

Drug(s) Affected By Epidermal growth factor receptor (EGFR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BIBW 2992	DMTKD7Q	Non-small-cell lung cancer	2C25.Y	Approved	[138]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[45]
Erlotinib	DMCMBHA	Adrenal gland neoplasm		Approved	[139]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[140]
Gemcitabine	DMSE3I7	Anterior urethra cancer		Approved	[141]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[142]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[143]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[144]
Selenium	DM25CGV	N. A.	N. A.	Approved	[145]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[146]

Drug(s) Affected By Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN (PTEN)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[147]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[67]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[148]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[95]
Cladribine	DM3JDRP	Hairy cell leukaemia	2A82.2	Approved	[149]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[150]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[151]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[152]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[153]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[154]

Drug(s) Affected By Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (PIK3CA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[65]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[155]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[83]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[156]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[120]
Adenosine triphosphate	DM79F6G	Malnutrition	5B50-5B71	Approved	[77]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[121]
Cantharidin	DMBP5N3	Molluscum contagiosum infection	1E76	Approved	[157]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[158]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[26]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
PI3-kinase gamma (PIK3CG)	TTHBTOP	PK3CG_HUMAN	Modulator	[3]
Serine/threonine-protein kinase mTOR (mTOR)	TTCJG29	MTOR_HUMAN	Modulator	[4]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Atos homolog protein A (ATOSA)	OTWFM5G0	ATOSA_HUMAN	Gene/Protein Processing	[5]
Cyclin-G2 (CCNG2)	OTII38K2	CCNG2_HUMAN	Gene/Protein Processing	[5]
Epidermal growth factor receptor (EGFR)	OTAPLO1S	EGFR_HUMAN	Drug Response	[5]
Eukaryotic translation initiation factor 4E-binding protein 1 (EIF4EBP1)	OTHBQVD5	4EBP1_HUMAN	Post-Translational Modifications	[6]
G1/S-specific cyclin-D1 (CCND1)	OT8HPTKJ	CCND1_HUMAN	Gene/Protein Processing	[3]
Hepatocyte growth factor receptor (MET)	OT7K55MU	MET_HUMAN	Gene/Protein Processing	[5]
Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)	OT2YYI1A	MCL1_HUMAN	Gene/Protein Processing	[5]
Mitogen-activated protein kinase 1 (MAPK1)	OTH85PI5	MK01_HUMAN	Post-Translational Modifications	[3]
Mitogen-activated protein kinase 3 (MAPK3)	OTCYKGKO	MK03_HUMAN	Post-Translational Modifications	[3]
Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN (PTEN)	OTOWDUNT	PTEN_HUMAN	Drug Response	[5]

References

• [1] Clinical pipeline report, company report or official report of Roche.
• [2] Clinical pipeline report, company report or official report of Genentech (2011).
• [3] GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. Mol Cancer Ther. 2011 Dec;10(12):2426-36.
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).
• [5] Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models. Clin Cancer Res. 2012 Dec 15;18(24):6771-83. doi: 10.1158/1078-0432.CCR-12-2347. Epub 2012 Nov 7.
• [6] Modulation of Akt/mTOR signaling overcomes sunitinib resistance in renal and prostate cancer cells. Mol Cancer Ther. 2012 Jul;11(7):1510-7. doi: 10.1158/1535-7163.MCT-11-0907. Epub 2012 Apr 24.
• [7] Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
• [8] Advances in kinase targeting: current clinical use and clinical trials. Trends Pharmacol Sci. 2014 Nov;35(11):604-20.
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] Mammalian target of rapamycin, its mode of action and clinical response in metastatic clear cell carcinoma. Gan To Kagaku Ryoho. 2009 Jul;36(7):1076-9.
• [11] Natural products to drugs: natural product-derived compounds in clinical trials. Nat Prod Rep. 2008 Jun;25(3):475-516.
• [12] A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
• [13] Dramatic suppression of colorectal cancer cell growth by the dual mTORC1 and mTORC2 inhibitor AZD-2014. Biochem Biophys Res Commun. 2014 Jan 10;443(2):406-12.
• [14] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [15] BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110 and p110 activities in tumor cell lines and xenograft models.Mol Cancer Ther.2013 Nov;12(11):2319-30.
• [16] PI3K-delta and PI3K-gamma inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol. 2013 Nov 21;20(11):1364-74.
• [17] Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44.
• [18] Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies. Clin Cancer Res. 2014 Mar 15;20(6):1656-65.
• [19] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2155).
• [20] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2156).
• [21] An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo.Cancer Chemother Pharmacol.2013 Apr;71(4):867-81.
• [22] Transcriptomic Analysis of Stem Cells Treated with Moringin or Cannabidiol: Analogies and Differences in Inflammation Pathways. Int J Mol Sci. 2019 Nov 30;20(23):6039. doi: 10.3390/ijms20236039.
• [23] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [24] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [25] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [26] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [27] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [28] Drug-induced endoplasmic reticulum and oxidative stress responses independently sensitize toward TNF-mediated hepatotoxicity. Toxicol Sci. 2014 Jul;140(1):144-59. doi: 10.1093/toxsci/kfu072. Epub 2014 Apr 20.
• [29] Genetic and epigenetic changes in the common 1p36 deletion in neuroblastoma tumours. Br J Cancer. 2007 Nov 19;97(10):1416-24. doi: 10.1038/sj.bjc.6604032. Epub 2007 Oct 16.
• [30] Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells. Biomark Insights. 2016 Aug 24;11:113-21.
• [31] Genome-wide analysis of BEAS-2B cells exposed to trivalent arsenicals and dimethylthioarsinic acid. Toxicology. 2010 Jan 31;268(1-2):31-9.
• [32] Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
• [33] Evidence of securin-mediated resistance to gefitinib-induced apoptosis in human cancer cells. Chem Biol Interact. 2013 Apr 25;203(2):412-22. doi: 10.1016/j.cbi.2013.03.011. Epub 2013 Mar 22.
• [34] Cigarette smoke and asbestos activate poly-ADP-ribose polymerase in alveolar epithelial cells. J Investig Med. 2001 Jan;49(1):68-76. doi: 10.2310/6650.2001.34092.
• [35] Apoptotic signaling pathways induced by nitric oxide in human lymphoblastoid cells expressing wild-type or mutant p53. Cancer Res. 2004 May 1;64(9):3022-9. doi: 10.1158/0008-5472.can-03-1880.
• [36] The antidepressants imipramine, clomipramine, and citalopram induce apoptosis in human acute myeloid leukemia HL-60 cells via caspase-3 activation. J Biochem Mol Toxicol. 1999;13(6):338-47. doi: 10.1002/(sici)1099-0461(1999)13:6<338::aid-jbt8>3.0.co;2-7.
• [37] Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line. Clin Cancer Res. 2000 Mar;6(3):891-900.
• [38] Investigation of molecular mechanisms underlying the antiproliferative effects of colchicine against PC3 prostate cancer cells. Toxicol In Vitro. 2021 Jun;73:105138. doi: 10.1016/j.tiv.2021.105138. Epub 2021 Mar 6.
• [39] Sulindac enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human lung cancer. Mol Cancer Ther. 2005 Feb;4(2):291-304.
• [40] Methotrexate induces poly(ADP-ribose) polymerase-dependent, caspase 3-independent apoptosis in subsets of proliferating CD4+ T cells. Clin Exp Immunol. 2007 May;148(2):288-95. doi: 10.1111/j.1365-2249.2007.03335.x. Epub 2007 Feb 7.
• [41] The nonsteroidal anti-inflammatory drugs aspirin and indomethacin attenuate beta-catenin/TCF-4 signaling. Oncogene. 2001 Feb 1;20(5):645-53. doi: 10.1038/sj.onc.1204123.
• [42] Novel mechanism of cannabidiol-induced apoptosis in breast cancer cell lines. Breast. 2018 Oct;41:34-41. doi: 10.1016/j.breast.2018.06.009. Epub 2018 Jun 22.
• [43] -Carotene Induces Apoptosis in Human Esophageal Squamous Cell Carcinoma Cell Lines via the Cav-1/AKT/NF-B Signaling Pathway. J Biochem Mol Toxicol. 2016 Mar;30(3):148-57. doi: 10.1002/jbt.21773. Epub 2016 Jan 6.
• [44] Cross-talk between non-genomic and genomic signalling pathways--distinct effect profiles of environmental estrogens. Toxicol Appl Pharmacol. 2010 Jun 1;245(2):160-70. doi: 10.1016/j.taap.2010.02.015. Epub 2010 Mar 4.
• [45] Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res. 2006 Jun 1;66(11):5542-8. doi: 10.1158/0008-5472.CAN-05-4620.
• [46] BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile. J Biochem Mol Toxicol. 2019 May;33(5):e22286. doi: 10.1002/jbt.22286. Epub 2019 Jan 23.
• [47] Resveratrol attenuates senescence of adipose-derived mesenchymal stem cells and restores their paracrine effects on promoting insulin secretion of INS-1 cells through Pim-1. Eur Rev Med Pharmacol Sci. 2016;20(6):1203-13.
• [48] Ribavirin augments doxorubicin's efficacy in human hepatocellular carcinoma through inhibiting doxorubicin-induced eIF4E activation. J Biochem Mol Toxicol. 2018 Jan;32(1). doi: 10.1002/jbt.22007. Epub 2017 Nov 7.
• [49] Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells. J Pharmacol Exp Ther. 2001 Sep;298(3):976-85.
• [50] Treatment with anticancer agents induces dysregulation of specific Wnt signaling pathways in human ovarian luteinized granulosa cells in vitro. Toxicol Sci. 2013 Nov;136(1):183-92. doi: 10.1093/toxsci/kft175. Epub 2013 Aug 16.
• [51] Progesterone increases csk homologous kinase in HMC-1560 human mast cells and reduces cell proliferation. J Cell Biochem. 2007 Dec 1;102(5):1271-80. doi: 10.1002/jcb.21357.
• [52] Cannabidiol upregulates melanogenesis through CB1 dependent pathway by activating p38 MAPK and p42/44 MAPK. Chem Biol Interact. 2017 Aug 1;273:107-114. doi: 10.1016/j.cbi.2017.06.005. Epub 2017 Jun 7.
• [53] Sertraline, an antidepressant, induces apoptosis in hepatic cells through the mitogen-activated protein kinase pathway. Toxicol Sci. 2014 Feb;137(2):404-15. doi: 10.1093/toxsci/kft254. Epub 2013 Nov 5.
• [54] Growth stimulation of human pulmonary adenocarcinoma cells and small airway epithelial cells by beta-carotene via activation of cAMP, PKA, CREB and ERK1/2. Int J Cancer. 2006 Mar 15;118(6):1370-80. doi: 10.1002/ijc.21537.
• [55] Estrogen and pure antiestrogen fulvestrant (ICI 182 780) augment cell-matrigel adhesion of MCF-7 breast cancer cells through a novel G protein coupled estrogen receptor (GPR30)-to-calpain signaling axis. Toxicol Appl Pharmacol. 2014 Mar 1;275(2):176-81. doi: 10.1016/j.taap.2014.01.005. Epub 2014 Jan 17.
• [56] Inhibition of activator protein 1 by barbiturates is mediated by differential effects on mitogen-activated protein kinases and the small G proteins ras and rac-1. J Pharmacol Exp Ther. 2004 Dec;311(3):1232-40. doi: 10.1124/jpet.104.071332. Epub 2004 Jul 19.
• [57] Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance. Breast Cancer Res Treat. 2010 Feb;119(3):575-91. doi: 10.1007/s10549-009-0355-8. Epub 2009 Mar 15.
• [58] Effect of histamine H1 receptor antagonists on TARC/CCL17 and MDC/CCL22 production from CD14+ cells induced by antigenic stimulation in vitro. Int Arch Allergy Immunol. 2011;155(1):38-51. doi: 10.1159/000318720. Epub 2010 Nov 25.
• [59] SIRT3 Mediates the Antioxidant Effect of Hydrogen Sulfide in Endothelial Cells. Antioxid Redox Signal. 2016 Feb 20;24(6):329-43. doi: 10.1089/ars.2015.6331. Epub 2015 Nov 10.
• [60] Downregulation of mitogen-activated protein kinases (MAPKs) in chronic ethanol-induced fatty liver. Toxicol Mech Methods. 2020 Jul;30(6):407-416. doi: 10.1080/15376516.2020.1747126. Epub 2020 Apr 1.
• [61] A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci U S A. 2007 Oct 16;104(42):16657-62. doi: 10.1073/pnas.0707936104. Epub 2007 Oct 9.
• [62] The stent-eluting drugs sirolimus and paclitaxel suppress healing of the endothelium by induction of autophagy. Am J Pathol. 2009 Nov;175(5):2226-34.
• [63] Modulation of apoptosis in HaCaT keratinocytes via differential regulation of ERK signaling pathway by flavonoids. J Biol Chem. 2005 Sep 9;280(36):31498-507. doi: 10.1074/jbc.M505537200. Epub 2005 Jul 13.
• [64] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [65] Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front Physiol. 2016 Nov 24;7:559. doi: 10.3389/fphys.2016.00559. eCollection 2016.
• [66] Cannabidiol Activates Neuronal Precursor Genes in Human Gingival Mesenchymal Stromal Cells. J Cell Biochem. 2017 Jun;118(6):1531-1546. doi: 10.1002/jcb.25815. Epub 2016 Dec 29.
• [67] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [68] Arsenic trioxide reduces the expression of E2F1, cyclin E, and phosphorylation of PI3K signaling molecules in acute leukemia cells. Environ Toxicol. 2021 Sep;36(9):1785-1792. doi: 10.1002/tox.23299. Epub 2021 May 27.
• [69] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [70] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [71] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [72] Quercetin blocks airway epithelial cell chemokine expression. Am J Respir Cell Mol Biol. 2006 Nov;35(5):602-10. doi: 10.1165/rcmb.2006-0149OC. Epub 2006 Jun 22.
• [73] Decitabine up-regulates S100A2 expression and synergizes with IFN-gamma to kill uveal melanoma cells. Clin Cancer Res. 2007 Sep 1;13(17):5219-25. doi: 10.1158/1078-0432.CCR-07-0816.
• [74] A sensitized RNA interference screen identifies a novel role for the PI3K p110 isoform in medulloblastoma cell proliferation and chemoresistance. Mol Cancer Res. 2011 Jul;9(7):925-35. doi: 10.1158/1541-7786.MCR-10-0200. Epub 2011 Jun 7.
• [75] Promyelocytic leukemia retinoid signaling targets regulate apoptosis,tissue factor and thrombomodulin expression. Haematologica. 2004 Mar;89(3):286-95.
• [76] Resveratrol is a class IA phosphoinositide 3-kinase inhibitor. Biochem J. 2007 Sep 15;406(3):511-8. doi: 10.1042/BJ20070236.
• [77] The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J Med Chem. 2008 Sep 25;51(18):5522-32. doi: 10.1021/jm800295d.
• [78] High-throughput ectopic expression screen for tamoxifen resistance identifies an atypical kinase that blocks autophagy. Proc Natl Acad Sci U S A. 2011 Feb 1;108(5):2058-63.
• [79] ROS-dependent DNA damage contributes to crizotinib-induced hepatotoxicity via the apoptotic pathway. Toxicol Appl Pharmacol. 2019 Nov 15;383:114768. doi: 10.1016/j.taap.2019.114768. Epub 2019 Oct 19.
• [80] Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification. Mol Cancer Ther. 2012 Jul;11(7):1557-64. doi: 10.1158/1535-7163.MCT-11-0934. Epub 2012 Jun 22.
• [81] An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
• [82] Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
• [83] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [84] All-trans retinoic acid inhibits the cell proliferation but enhances the cell invasion through up-regulation of c-met in pancreatic cancer cells. Cancer Lett. 2005 Jun 28;224(2):303-10. doi: 10.1016/j.canlet.2004.10.016. Epub 2004 Dec 8.
• [85] Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
• [86] Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab. Clin Cancer Res. 2009 Jun 15;15(12):4147-56. doi: 10.1158/1078-0432.CCR-08-2814. Epub 2009 Jun 9.
• [87] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [88] Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
• [89] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [90] Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
• [91] Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessment. Arch Toxicol. 2016 Nov;90(11):2763-2777.
• [92] The DNA damaging agent VP16 induces the expression of a subset of ligands from the EGF system in bladder cancer cells, whereas none of the four EGF receptors are induced. Mol Cell Biochem. 2004 May;260(1-2):129-35. doi: 10.1023/b:mcbi.0000026063.96267.98.
• [93] Sulindac metabolites induce proteosomal and lysosomal degradation of the epidermal growth factor receptor. Cancer Prev Res (Phila). 2010 Apr;3(4):560-72. doi: 10.1158/1940-6207.CAPR-09-0159. Epub 2010 Mar 23.
• [94] Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
• [95] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [96] Inhibition of prostate cancer cell colony formation by the flavonoid quercetin correlates with modulation of specific regulatory genes. Clin Diagn Lab Immunol. 2004 Jan;11(1):63-9. doi: 10.1128/cdli.11.1.63-69.2004.
• [97] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [98] Rosiglitazone, an Agonist of PPARgamma, Inhibits Non-Small Cell Carcinoma Cell Proliferation In Part through Activation of Tumor Sclerosis Complex-2. PPAR Res. 2007;2007:29632. doi: 10.1155/2007/29632.
• [99] Involvement of C/EBP-related signaling pathway in methamphetamine-induced neuronal autophagy and apoptosis. Toxicol Lett. 2019 Sep 15;312:11-21. doi: 10.1016/j.toxlet.2019.05.003. Epub 2019 May 3.
• [100] Mechanism of cisplatin proximal tubule toxicity revealed by integrating transcriptomics, proteomics, metabolomics and biokinetics. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):117-27.
• [101] Aberrant expression of TSC2 gene in the newly diagnosed acute leukemia. Leuk Res. 2009 Jul;33(7):891-7. doi: 10.1016/j.leukres.2009.01.041. Epub 2009 Feb 27.
• [102] Beta-carotene and apocarotenals promote retinoid signaling in BEAS-2B human bronchioepithelial cells. Arch Biochem Biophys. 2006 Nov 1;455(1):48-60.
• [103] The role of MITF and Mcl-1 proteins in the antiproliferative and proapoptotic effect of ciprofloxacin in amelanotic melanoma cells: In silico and in vitro study. Toxicol In Vitro. 2020 Aug;66:104884. doi: 10.1016/j.tiv.2020.104884. Epub 2020 May 8.
• [104] Peripheral blood expression of nuclear factor-kappab-regulated genes is associated with rheumatoid arthritis disease activity and responds differentially to anti-tumor necrosis factor-alpha versus methotrexate. J Rheumatol. 2007 Sep;34(9):1817-22. Epub 2007 Aug 1.
• [105] Quercetin downregulates Mcl-1 by acting on mRNA stability and protein degradation. Br J Cancer. 2011 Jul 12;105(2):221-30. doi: 10.1038/bjc.2011.229.
• [106] Multifaceted preventive effects of single agent quercetin on a human prostate adenocarcinoma cell line (PC-3): implications for nutritional transcriptomics and multi-target therapy. Med Oncol. 2011 Dec;28(4):1395-404. doi: 10.1007/s12032-010-9603-3. Epub 2010 Jul 2.
• [107] D-Penicillamine targets metastatic melanoma cells with induction of the unfolded protein response (UPR) and Noxa (PMAIP1)-dependent mitochondrial apoptosis. Apoptosis. 2012 Oct;17(10):1079-94.
• [108] Anti-cancer properties of glucosamine-hydrochloride in YD-8 human oral cancer cells: Induction of the caspase-dependent apoptosis and down-regulation of HIF-1. Toxicol In Vitro. 2012 Feb;26(1):42-50. doi: 10.1016/j.tiv.2011.10.005. Epub 2011 Oct 13.
• [109] Ethacrynic acid and a derivative enhance apoptosis in arsenic trioxide-treated myeloid leukemia and lymphoma cells: the role of glutathione S-transferase p1-1. Clin Cancer Res. 2012 Dec 15;18(24):6690-701. doi: 10.1158/1078-0432.CCR-12-0770. Epub 2012 Oct 18.
• [110] Frenolicin B Targets Peroxiredoxin 1 and Glutaredoxin 3 to Trigger ROS/4E-BP1-Mediated Antitumor Effects. Cell Chem Biol. 2019 Mar 21;26(3):366-377.e12. doi: 10.1016/j.chembiol.2018.11.013. Epub 2019 Jan 17.
• [111] A gene signature-based approach identifies thioridazine as an inhibitor of phosphatidylinositol-3'-kinase (PI3K)/AKT pathway in ovarian cancer cells. Gynecol Oncol. 2011 Jan;120(1):121-7. doi: 10.1016/j.ygyno.2010.10.003. Epub 2010 Oct 29.
• [112] Benzodithiophenes potentiate differentiation of acute promyelocytic leukemia cells by lowering the threshold for ligand-mediated corepressor/coactivator exchange with retinoic acid receptor alpha and enhancing changes in all-trans-retinoic acid-regulated gene expression. Cancer Res. 2005 Sep 1;65(17):7856-65. doi: 10.1158/0008-5472.CAN-05-1056.
• [113] Arsenic trioxide potentiates the anti-cancer activities of sorafenib against hepatocellular carcinoma by inhibiting Akt activation. Tumour Biol. 2015 Apr;36(4):2323-34. doi: 10.1007/s13277-014-2839-3. Epub 2014 Nov 22.
• [114] Keratinocyte-derived IL-36gama plays a role in hydroquinone-induced chemical leukoderma through inhibition of melanogenesis in human epidermal melanocytes. Arch Toxicol. 2019 Aug;93(8):2307-2320.
• [115] Androgen receptor-mTOR crosstalk is regulated by testosterone availability: implication for prostate cancer cell survival. Anticancer Res. 2010 Oct;30(10):3895-901.
• [116] A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemia. Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3378-83.
• [117] The neuroprotective action of the mood stabilizing drugs lithium chloride and sodium valproate is mediated through the up-regulation of the homeodomain protein Six1. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):124-34.
• [118] Moving toward integrating gene expression profiling into high-throughput testing: a gene expression biomarker accurately predicts estrogen receptor alpha modulation in a microarray compendium. Toxicol Sci. 2016 May;151(1):88-103.
• [119] Transcriptome-based functional classifiers for direct immunotoxicity. Arch Toxicol. 2014 Mar;88(3):673-89.
• [120] Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
• [121] Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
• [122] Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
• [123] 17-Estradiol Activates HSF1 via MAPK Signaling in ER-Positive Breast Cancer Cells. Cancers (Basel). 2019 Oct 11;11(10):1533. doi: 10.3390/cancers11101533.
• [124] LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A. 2018 May 1;115(18):E4179-E4188.
• [125] Effect of retinoic acid on gene expression in human conjunctival epithelium: secretory phospholipase A2 mediates retinoic acid induction of MUC16. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4050-61.
• [126] Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res. 2005 Dec 15;65(24):11676-88.
• [127] Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3K inhibition through PIK3IP1. Cell Cycle. 2013 Jun 15;12(12):1892-900. doi: 10.4161/cc.24928. Epub 2013 May 15.
• [128] Single-cell Transcriptome Mapping Identifies Common and Cell-type Specific Genes Affected by Acute Delta9-tetrahydrocannabinol in Humans. Sci Rep. 2020 Feb 26;10(1):3450. doi: 10.1038/s41598-020-59827-1.
• [129] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [130] Antidepressant drug sertraline modulates AMPK-MTOR signaling-mediated autophagy via targeting mitochondrial VDAC1 protein. Autophagy. 2021 Oct;17(10):2783-2799. doi: 10.1080/15548627.2020.1841953. Epub 2020 Nov 9.
• [131] eNOS activation mediated by AMPK after stimulation of endothelial cells with histamine or thrombin is dependent on LKB1. Biochim Biophys Acta. 2011 Feb;1813(2):322-31. doi: 10.1016/j.bbamcr.2010.12.001. Epub 2010 Dec 9.
• [132] 2-Deoxy-D-glucose cooperates with arsenic trioxide to induce apoptosis in leukemia cells: involvement of IGF-1R-regulated Akt/mTOR, MEK/ERK and LKB-1/AMPK signaling pathways. Biochem Pharmacol. 2012 Dec 15;84(12):1604-16. doi: 10.1016/j.bcp.2012.09.022. Epub 2012 Oct 5.
• [133] Effects of metformin and pioglitazone combination on apoptosis and AMPK/mTOR signaling pathway in human anaplastic thyroid cancer cells. J Biochem Mol Toxicol. 2020 Oct;34(10):e22547. doi: 10.1002/jbt.22547. Epub 2020 Jun 26.
• [134] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [135] Resveratrol activates duodenal Sirt1 to reverse insulin resistance in rats through a neuronal network. Nat Med. 2015 May;21(5):498-505. doi: 10.1038/nm.3821. Epub 2015 Apr 6.
• [136] Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis. Oncogene. 2010 Mar 4;29(9):1329-38. doi: 10.1038/onc.2009.425. Epub 2009 Nov 30.
• [137] Effect of aflatoxin B(1), benzo[a]pyrene, and methapyrilene on transcriptomic and epigenetic alterations in human liver HepaRG cells. Food Chem Toxicol. 2018 Nov;121:214-223. doi: 10.1016/j.fct.2018.08.034. Epub 2018 Aug 26.
• [138] Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors. J Med Chem. 2011 Mar 10;54(5):1347-55. doi: 10.1021/jm101396q. Epub 2011 Feb 15.
• [139] Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004 May 20;350(21):2129-39. doi: 10.1056/NEJMoa040938. Epub 2004 Apr 29.
• [140] The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res. 2005 Jan 1;65(1):18-25.
• [141] A fine-needle aspirate-based vulnerability assay identifies polo-like kinase 1 as a mediator of gemcitabine resistance in pancreatic cancer. Mol Cancer Ther. 2010 Feb;9(2):311-8. doi: 10.1158/1535-7163.MCT-09-0693. Epub 2010 Jan 26.
• [142] Prediction of chemosensitivity using multigene analysis in head and neck squamous cell carcinoma. Oncology. 2007;73(1-2):104-11. doi: 10.1159/000120998. Epub 2008 Mar 13.
• [143] Sertraline induces endoplasmic reticulum stress in hepatic cells. Toxicology. 2014 Aug 1;322:78-88. doi: 10.1016/j.tox.2014.05.007. Epub 2014 May 24.
• [144] Minimal peroxide exposure of neuronal cells induces multifaceted adaptive responses. PLoS One. 2010 Dec 17;5(12):e14352. doi: 10.1371/journal.pone.0014352.
• [145] Inhibition of invasion and induction of apoptosis by selenium in human malignant brain tumour cells in vitro. Int J Oncol. 2007 May;30(5):1263-71.
• [146] Ligand-dependent activation of the epidermal growth factor receptor by secondary bile acids in polarizing colon cancer cells. Surgery. 2005 Sep;138(3):415-21. doi: 10.1016/j.surg.2005.06.030.
• [147] Role of miRNA in the regulation of cannabidiol-mediated apoptosis in neuroblastoma cells. Oncotarget. 2019 Jan 1;10(1):45-59. doi: 10.18632/oncotarget.26534. eCollection 2019 Jan 1.
• [148] Astaxanthin protects mesenchymal stem cells from oxidative stress by direct scavenging of free radicals and modulation of cell signaling. Chem Biol Interact. 2021 Jan 5;333:109324. doi: 10.1016/j.cbi.2020.109324. Epub 2020 Nov 17.
• [149] Comparative effects of retinoic acid, vitamin D and resveratrol alone and in combination with adenosine analogues on methylation and expression of phosphatase and tensin homologue tumour suppressor gene in breast cancer cells. Br J Nutr. 2012 Mar;107(6):781-90. doi: 10.1017/S0007114511003631. Epub 2011 Aug 1.
• [150] Quercetin and Its Fermented Extract as a Potential Inhibitor of Bisphenol A-Exposed HT-29 Colon Cancer Cells' Viability. Int J Mol Sci. 2023 Mar 15;24(6):5604. doi: 10.3390/ijms24065604.
• [151] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [152] Arsenic trioxide inhibits the proliferation of myeloma cell line through notch signaling pathway. Cancer Cell Int. 2013 Mar 13;13(1):25. doi: 10.1186/1475-2867-13-25.
• [153] Mechanism of thalidomide to enhance cytotoxicity of temozolomide in U251-MG glioma cells in vitro. Chin Med J (Engl). 2009 Jun 5;122(11):1260-6.
• [154] The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
• [155] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [156] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [157] Cantharidin suppresses gastric cancer cell migration/invasion by inhibiting the PI3K/Akt signaling pathway via CCAT1. Chem Biol Interact. 2020 Feb 1;317:108939. doi: 10.1016/j.cbi.2020.108939. Epub 2020 Jan 13.
• [158] Atorvastatin induces MicroRNA-145 expression in HEPG2 cells via regulation of the PI3K/AKT signalling pathway. Chem Biol Interact. 2018 May 1;287:32-40. doi: 10.1016/j.cbi.2018.04.005. Epub 2018 Apr 6.